TCT

This channel contains news about the annual Transcatheter Cardiovascular Therapeutics (TCT) conference presented by the Cardiovascular Research Foundation (CRF). It includes coverage from the annual meeting and links CRF news. TCT is the premier conference for the subspecialty of interventional cardiology, including the new subspecialty areas of transcatheter structural heart procedures.

An illustration of the Recor renal denervation ablation balloon at work in the renal artery.. Renal Denervation Recor RDN ablation balloon #TCT2021

News | Hypertension

Renal Denervation Combined With Medication Can Treat Resistant Hypertension

November 9, 2021 — Six-month outcomes from the randomized RADIANCE-HTN TRIO Trial comparing endovascular ultrasound ...

November 09, 2021

$Abbott's fractional flow reserve (FFR) system. #TCT #TCT21 #FAME3$

News | FFR Technologies

FAME 3 Study Finds FFR Guided PCI Did Not Perform as Well at One-year Compared to Bypass Surgery

November 9, 2021 — The primary results of the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation ...

November 09, 2021

The Alvimedica Cre8 Evo Cre8 polymer-free amphilimus-eluting stent

News | Stents

Patients With Diabetes Undergoing PCI Have Less Target Lesion Failure With Amphilimus-eluting Stents

November 9, 2021 — Results from SUGAR trial, a randomized, controlled, multicenter trial conducted exclusively in ...

November 09, 2021

Sponsored Content

New procedures, new workflows, and increased collaboration across traditionally siloed areas are increasing the need for better cardiology data management tools.

Blog | Enterprise Imaging

BLOG: Capturing the Full Value of Complex Cardiology Data

The optimal delivery of cardiac care is evolving rapidly. A growing number of patients combined with innovative new ...

November 03, 2022

TAVR CT image reconstruction of an implanted Medtronic CoreValve. #TCT21 #TCT #TAVR #SURTAVI

News | Heart Valve Technology

Intermediate-risk Patients Have Similar Five-year Outcomes With Transcatheter or Surgical Aortic Valve Replacement

November 9, 2021 — New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality ...

November 09, 2021

A PARTNER 3 trial economic analysis shows for low surgical risk patients, TAVR is cost-saving compared with SAVR. TAVR Sapien Valve visualized using a GE guidance software. #TCT2021

News | Structural Heart

TAVR Is Cost Effective Compared With Surgical Replacement for Low-risk Patients

November 9, 2021 — An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve ...

November 09, 2021

News | FFR Technologies

QFR Technology for Advanced Coronary Artery Disease Leads to Improved Outcomes

November 9, 2021 — Use of a novel technique called the quantitative flow ratio (QFR) to precisely identify and measure ...

November 09, 2021

A new large-scale, real-world analysis of Centers for Medicare and Medicaid Services (CMS) outcomes data from of peripheral vascular interventions guided by intravascular ultrasound (IVUS) showed a 32% reduction in major adverse limb events, such as amputations, during lower extremity arterial intervention.

News | Intra-Vascular Ultrasound (IVUS)

IVUS Improved Outcomes in Largest Real-world Analysis of Lower Extremity Peripheral Vascular Interventions

November 9 2021 — A new large-scale, real-world analysis of Centers for Medicare and Medicaid Services (CMS) outcomes ...

November 09, 2021

The two FDA-cleared transcatheter LAA occlusion devices on the U.S. market were compared in the SWISS-APERO and SEAL FLX trials presented at TCT 2021. Left is the Abbott Amulet device, right is the newest generation Watchman FLX device.

News | Left Atrial Appendage (LAA) Occluders

First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage ...

November 08, 2021

The Edwards Lifesciences Evoque transcatheter tricuspid valve replacement system demonstrated sustained favorable patient outcomes at six months in the TRISCEND study.

News | Structural Heart

Six-Month Outcomes Positive for Transfemoral Tricuspid Valve in Tricuspid Regurgitation Patients

November 8, 2021 — Results from a clinical trial of the Edwards Lifesciences Evoque transcatheter tricuspid valve ...

November 08, 2021

The ControlRad device collimates the area of interest where the physicians are working, and reduces the dose significantly to peripheral areas in the image.

News | Radiation Dose Management

Beaumont Uses New Cardiac Cath Lab Technology to Reduce Radiation Exposure

November 5, 2021 – An FDA-approved device used during cardiac cath lab procedures cut radiation exposure for ...

November 05, 2021

Videos | FFR Technologies

VIDEO: Example of the Medis QFR Angiography Image Derived FFR System

This is an example of the Medis Medical Imaging Quantitative Flow Ratio (QFR) system that offers a fractional flow ...

December 16, 2020

Videos | Robotic Systems

VIDEO: Corindus CorPath Robotic PCI System For The Cardiac Cath Lab

This is an example of the Siemens Corindus CorPath Cath lab robotic system being used for a percutaneous coronary ...

December 16, 2020

COVID-19 cardiology related content continues to be among the top performers on the DAIC website in November 2020. TAVR also topped headlines with Boston Scientific taking its Lotus valve off the market and a review of TAVR registry data showing it is now the dominant method of aortic valve replacement in the United States. #DAIC

Feature | Cardiovascular Business | Dave Fornell, Editor

December 1, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

December 01, 2020

Figure 1: PROTECT III found, when compared to intra-aortic balloon pump (IABP), Impella use led to a 29% reduction in MACCE at 90 days.

News | Hemodynamic Support Devices

Largest Study of Hemodynamically Supported High-Risk PCI Patients Finds More Complete Revascularization With Impella

November 12, 2020 — Abiomed recently announced new PROTECT III study data that demonstrates reduced rates of MACCE ...

November 12, 2020

Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020

Feature | TCT | Dave Fornell, Editor

Top 10 Takeaways on Interventional Technologies at TCT 2020

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

October 29, 2020